Skip to content
Search

Latest Stories

Data shows drop in HIV diagnoses; RPS seeks availability of PrEP tablets at community pharmacies

While the latest report by the UK Health Security Agency (UKHSA) showed a 33 per cent drop in total number of new HIV diagnoses in England in 2020, the Royal Pharmaceutical Society has called on the government to make the pre-exposure prophylaxis (PrEP) tablets available at community pharmacies across Great Britain.

PrEP is available free through sexual health clinics and offers almost full protection from HIV when taken as recommended prior to sex or injecting drugs.


RPS president Professor Claire Anderson said: “There is a clear opportunity to drive down rates of HIV infection by expanding provision of pre-exposure prophylaxis (PrEP) to community pharmacies and GP practices as part of the government’s HIV Action Plan."

HIV Action Plan (2022 to 2025) set out by the government aims to end HIV transmission and AIDS, to decrease the number of HIV-related deaths and to end HIV-related stigma by 2030.

She added: “Community pharmacies are highly trusted and conveniently located, providing a much wider reach than specialist services can on their own. Pharmacies see those who may be reluctant or unable to attend other health services, play a vital role in reducing harm, and provide rapid access to health and care."

She urged the government “to make PrEP available through community pharmacies as soon as possible.”

The UKSHA report said there were 2,630 new diagnoses in 2020 compared to 3,950 in 2019.

It noted that decline in new HIV diagnoses in England was sharpest in gay and bisexual men, which fell by 41 per cent between 2019 and 2020, while number of heterosexuals opting for diagnosis fell by 33 per cent during the period.

It highlighted that the Covid-19 pandemic has changed patterns of sexual behaviour, affected HIV testing and limited access to sexual health and HIV services, thus impacted the number of diagnoses, it said.

Dr Valerie Delpech, head of HIV Surveillance at UKHSA, said: “The continued decline in HIV diagnoses made in England is encouraging, but last year’s data needs to be considered in the context of a Covid-19 pandemic which saw prolonged and unprecedented public health restrictions, coupled with intense pressure on health services resulting in a decline in HIV testing overall.

“It is now crucial that we continue to ramp up testing and start people on treatment at the earliest possible opportunity.”

More For You

Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less